2016/17 Agency Business Plan - Further performance work

	Further performance	e related work	Original Due Date	Actual Delivery Date	Status (RAG)	Comments	Division / centre
	A Review on a bi-month can be monitored and	ally basis all regulatory actions finalised by VRMM whose impact I prioritise these for further study;	Q1-Q4		On track	This is ongoing and has helped identify future studies.	VRMM
	(i) compliance action; (ii) issuing advice who (iii) issuing advice to r	r basis all devices regulatory interventions including en the manufacturer is not taking any action and modify FSCAs where manufacturers actions are inadequate cases for further study; and	Q1-Q4			Reviewed on an ongoing basis by the monthly Technical Management Group Compliance meeting, which involves senior managers from across the Division.	Devices
,	C Annually undertake republic health outcome	eviews of at least two regulatory interventions to identify the es.	Q1-Q4		On track	The first review has commenced.	VRMM

RAG status	
Completed	
On track	
Risk of delay	(but still deliverable by end of 2016/17)
Significant rick of dolay	(i e will not be delivered till 2017/18)